Puma Biotech (PBYI) Tops Q4 EPS by 15c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. CSX
7. LRCX
8. LVS
9. KNX
10. KMI

Go back to Puma Biotech (PBYI) Tops Q4 EPS by 15c

Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results

February 25, 2021 4:05 PM EST

LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2020. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2020, compared to the fourth quarter and full year 2019.

Product revenue, net consists entirely of sales revenue from NERLYNX®, Pumas first commercial product. Net NERLYNX revenue in the fourth quarter of 2020 was $50.0 million, compared to $58.7 million in the fourth quarter of 2019. Net NERLYNX revenue for the full year 2020 was $196.7 million, compared to $211.6 million for the full year... More